Skip to main content

Chronic Hepatitis B

  • Chapter
  • First Online:
Liver Disease in Clinical Practice

Part of the book series: In Clinical Practice ((ICP))

  • 537 Accesses

Abstract

Hepatitis B virus (HBV) is a stealth virus that is transmitted by percutaneous route and leads to chronic hepatitis B (CHB) infection if exposed during infancy or early childhood. CHB is one of the leading causes of cirrhosis and hepatocellular carcinoma globally. Although there is yet a cure, effective strategies to minimise the impact of CHB include immunisation, antiviral therapy, and surveillance of liver-related complications. This chapter will review the key facts of HBV virology, natural history, diagnostic workup, and management advices for patients with CHB. The approach to special CHB populations including cirrhotic, immunosuppressed, and pregnant individuals will also be discussed. The potential clinical use of blood-based biomarkers and novel drugs for CHB will be explored.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 37.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 37.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Blumberg BS, Alter HJ, Visnich S. A “New” antigen in leukemia sera. JAMA. 1965;191:541–6.

    Article  CAS  PubMed  Google Scholar 

  2. Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383–403.

    Article  Google Scholar 

  3. Cox AL, El-Sayed MH, Kao JH, Lazarus JV, Lemoine M, Lok AS, et al. Progress towards elimination goals for viral hepatitis. Nat Rev Gastroenterol Hepatol. 2020;17(9):533–42.

    Article  PubMed  PubMed Central  Google Scholar 

  4. World Health Organization. Global hepatitis report 2017. Geneva: World Health Organization; 2017. p. 2017.

    Google Scholar 

  5. [Centers for Disease Control (CDC) and Prevention webpage:]. https://www.cdc.gov/hepatitis/hbv/perinatalxmtn.htm.

  6. Martinot-Peignoux M, Lapalus M, Asselah T, Marcellin P. HBsAg quantification: useful for monitoring natural history and treatment outcome. Liver Int. 2014;34(Suppl 1):97–107.

    Article  CAS  PubMed  Google Scholar 

  7. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. elife. 2012;1:e00049.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Rehermann B. Natural killer cells in viral hepatitis. Cell Mol Gastroenterol Hepatol. 2015;1(6):578–88.

    Article  PubMed  PubMed Central  Google Scholar 

  9. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98.

    Article  Google Scholar 

  10. Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–99.

    Article  PubMed  Google Scholar 

  11. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009;373(9663):582–92.

    Article  CAS  PubMed  Google Scholar 

  12. Bertoletti A, Kennedy PT. The immune tolerant phase of chronic HBV infection: new perspectives on an old concept. Cell Mol Immunol. 2015;12(3):258–63.

    Article  CAS  PubMed  Google Scholar 

  13. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295(1):65–73.

    Article  CAS  PubMed  Google Scholar 

  14. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347(3):168–74.

    Article  CAS  PubMed  Google Scholar 

  15. Liu J, Yang HI, Lee MH, Lu SN, Jen CL, Batrla-Utermann R, et al. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. Gut. 2014;63(10):1648–57.

    Article  CAS  PubMed  Google Scholar 

  16. Yuen MF, Wong DK, Fung J, Ip P, But D, Hung I, et al. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology. 2008;135(4):1192–9.

    Article  CAS  PubMed  Google Scholar 

  17. Yip TC, Chan HL, Wong VW, Tse YK, Lam KL, Wong GL. Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. J Hepatol. 2017;67(5):902–8.

    Article  CAS  PubMed  Google Scholar 

  18. Anderson RT, Choi HSJ, Lenz O, Peters MG, Janssen HLA, Mishra P, et al. Association between Seroclearance of hepatitis B surface antigen and long-term clinical outcomes of patients with chronic hepatitis B virus infection: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021;19(3):463–72.

    Article  CAS  PubMed  Google Scholar 

  19. Gill US, Zissimopoulos A, Al-Shamma S, Burke K, McPhail MJ, Barr DA, et al. Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk? J Infect Dis. 2015;211(3):374–82.

    Article  CAS  PubMed  Google Scholar 

  20. Lampertico P, Buti M, Fung S, Ahn SH, Chuang WL, Tak WY, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. Lancet Gastroenterol Hepatol. 2020;5(5):441–53.

    Article  PubMed  Google Scholar 

  21. Toyoda H, Leong J, Landis C, Atsukawa M, Watanabe T, Huang DQ, et al. Treatment and renal outcomes up to 96 weeks after tenofovir alafenamide switch from tenofovir disoproxil fumarate in routine practice. Hepatology. 2021;74(2):656–66.

    Article  CAS  PubMed  Google Scholar 

  22. Tsai NC, Marcellin P, Buti M, Washington MK, Lee SS, Chan S, et al. Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B. Dig Dis Sci. 2015;60(1):260–8.

    Article  CAS  PubMed  Google Scholar 

  23. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381(9865):468–75.

    Article  CAS  PubMed  Google Scholar 

  24. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013;58(1):98–107.

    Article  CAS  PubMed  Google Scholar 

  25. Papatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, van Boemmel F, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology. 2017;66(5):1444–53.

    Article  CAS  PubMed  Google Scholar 

  26. Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98.

    Article  CAS  PubMed  Google Scholar 

  27. Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology. 2010;52(4):1251–7.

    Article  CAS  PubMed  Google Scholar 

  28. Zoulim F, Mason WS. Reasons to consider earlier treatment of chronic HBV infections. Gut. 2012;61(3):333–6.

    Article  CAS  PubMed  Google Scholar 

  29. Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT. American Gastroenterological Association I. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):215–9; quiz e16–7.

    Article  CAS  PubMed  Google Scholar 

  30. Sonneveld MJ, Hansen BE, Brouwer WP, Chan HL, Piratvisuth T, Jia JD, et al. hbsag levels can be used to rule out cirrhosis in hbeag positive chronic hepatitis b: results from the sonic-b study. J Infect Dis. 2020;225(11):1967–73.

    Article  PubMed Central  Google Scholar 

  31. Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology. 2012;142(5):1140–1149.e3; quiz e13–4.

    Article  CAS  PubMed  Google Scholar 

  32. Wong DK, Seto WK, Cheung KS, Chong CK, Huang FY, Fung J, et al. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. Liver Int. 2017;37(7):995–1001.

    Article  CAS  PubMed  Google Scholar 

  33. Wang J, Shen T, Huang X, Kumar GR, Chen X, Zeng Z, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol. 2016;65(4):700–10.

    Article  CAS  PubMed  Google Scholar 

  34. Butler EK, Gersch J, McNamara A, Luk KC, Holzmayer V, de Medina M, et al. Hepatitis B virus serum DNA andRNA levels in Nucleos(t)ide analog-treated or untreated patients during chronic and acute infection. Hepatology. 2018;68(6):2106–17.

    Article  CAS  PubMed  Google Scholar 

  35. Mak LY, Cloherty G, Wong DK, Gersch J, Seto WK, Fung J, et al. HBV RNA profiles in patients with chronic hepatitis B under different disease phases and antiviral therapy. Hepatology. 2021;73(6):2167–79.

    Article  CAS  PubMed  Google Scholar 

  36. Seto WK, Liu KS, Mak LY, Cloherty G, Wong DK, Gersch J, et al. Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation. Gut. 2021;70(4):775–83.

    Article  PubMed  Google Scholar 

  37. Mak LY, Huang Q, Wong DK, Stamm L, Cheung KS, Ko KL, et al. Residual HBV DNA and pgRNA viraemia is associated with hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy. J Gastroenterol. 2021;56(5):479–88.

    Article  CAS  PubMed  Google Scholar 

  38. Hsu YC, Yip TC, Ho HJ, Wong VW, Huang YT, El-Serag HB, et al. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. J Hepatol. 2018;69(2):278–85.

    Article  PubMed  Google Scholar 

  39. Kim SU, Seo YS, Lee HA, Kim MN, Kim EH, Kim HY, et al. Validation of the CAMD score in patients with chronic hepatitis B virus infection receiving antiviral therapy. Clin Gastroenterol Hepatol. 2020;18(3):693–9. e1

    Article  CAS  PubMed  Google Scholar 

  40. Thimme R, Dandri M. Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B? J Hepatol. 2013;58(2):205–9.

    Article  PubMed  Google Scholar 

  41. Yang N, Bertoletti A. Advances in therapeutics for chronic hepatitis B. Hepatol Int. 2016;10(2):277–85.

    Article  PubMed  Google Scholar 

  42. Yuen MF, Chen DS, Dusheiko GM, Janssen HLA, Lau DTY, Locarnini SA, et al. Hepatitis B virus infection. Nat Rev Dis Primers. 2018;4:18035.

    Article  PubMed  Google Scholar 

  43. Ye J, Chen J. Interferon and hepatitis B: current and future perspectives. Front Immunol. 2021;12:733364.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Patrick Kennedy .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Hansi, N., Mak, L.LY., Gill, U., Kennedy, P. (2022). Chronic Hepatitis B. In: Cross, T. (eds) Liver Disease in Clinical Practice. In Clinical Practice. Springer, Cham. https://doi.org/10.1007/978-3-031-10012-3_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-10012-3_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-10011-6

  • Online ISBN: 978-3-031-10012-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics